Telix Pharmaceuticals Ltd has released a press release.
Telix H1 2025 Results Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- Telix H1 2025 Appendix 4D and Interim Report
- Historical Financials in USD and H12025 OPEX (Unaudited)
- Telix H1 2025 Results: Investor Webcast Notification
- Telix Reports US$204M Q2 Revenue, Up 63% YOY
- Gozellix Receives Permanent HCPCS Code
Later from Telix Pharmaceuticals
- Telix H1 2025 Results Announcement
- Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference
- Telix Provides Regulatory Update on TLX250-CDx
- Telix and FDA Agree Resubmission Pathway for Pixclara NDA
- Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals